Aug 6, 2026 06:45AM
Aug 6, 2026 06:45AM
Apr 30, 2026 06:30AM
Apr 21, 2026 08:37AM
Apr 21, 2026 06:45AM
Apr 21, 2026 06:45AM
Apr 20, 2026 06:48AM FDA grants priority review for Merck's KEYTRUDA combinations in bladder cancer
Apr 20, 2026 06:48AM
Apr 13, 2026 07:01AM
Apr 13, 2026 07:00AM
Mar 2, 2026 06:26AM
Feb 28, 2026 10:05AM
Feb 28, 2026 10:05AM
Feb 28, 2026 10:00AM WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carc
Feb 25, 2026 12:37PM
Feb 25, 2026 12:37PM
Feb 3, 2026 06:30AM
Nov 19, 2025 06:45AM
Nov 19, 2025 06:45AM
Oct 23, 2025 06:00AM
Oct 23, 2025 06:00AM FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain
Oct 18, 2025 10:35AM
Oct 15, 2025 06:45AM
Oct 15, 2025 06:45AM
Sep 19, 2025 06:45AM
Sep 19, 2025 06:45AM
Jul 29, 2025 06:30AM
Jul 10, 2025 06:45AM FDA accepts Merck's application for HIV two-drug regimen
Jul 10, 2025 06:45AM
Jul 2, 2025 06:45AM
Jul 2, 2025 06:45AM
Jun 13, 2025 11:43AM
Apr 27, 2025 12:00PM
Apr 24, 2025 06:30AM
Mar 27, 2025 11:01AM Merck (MRK) Reports Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous KEYTRUDA
Mar 27, 2025 11:01AM
Feb 25, 2025 06:45AM
Feb 25, 2025 06:45AM
Feb 4, 2025 06:30AM
Jan 27, 2025 06:45AM
Dec 17, 2024 06:46AM
Dec 17, 2024 06:45AM Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV
Dec 11, 2024 09:44AM
Jul 30, 2024 06:30AM
May 29, 2024 07:17AM
May 29, 2024 07:15AM
May 9, 2024 06:46AM
May 9, 2024 06:45AM
May 7, 2024 04:00PM Ligand Reports First Quarter 2024 Financial Results
Apr 29, 2024 09:01AM

15,656 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All